Bartosz Hudzik: Top 10 Advances in Thrombosis and Antithrombotic Therapy in 2025
Bartosz Hudzik, Editorial Consultant at JACC Case Reports, shared on LinkedIn:
“Top 10 Advances in Thrombosis and Antithrombotic Therapy (2025)
Clinical practice in cardiovascular medicine continues to evolve rapidly. This visual summary highlights key trials and registries shaping how we manage ACS, atrial fibrillation, and valve disease in 2025.
What stands out?
- Shorter and more targeted antiplatelet strategies after PCI
- Growing evidence supporting DOAC-based approaches in AF and select high-risk settings
- Re-thinking aspirin duration and intensity in ACS and post-CABG patients
- New data on valve thrombosis, bioprosthetic valves, and pregnancy outcomes with heart prostheses
- Persistent gaps where evidence is still urgently needed
Trials like TARGET-FIRST, NEO-MINDSET, TACSI, AQUATIC, COMBINE-AF, and PRESTIGE-AF are refining day-to-day decision-making, while registries such as ROPAC III remind us how much work remains in special populations.
As always, translating these findings into individualized patient care—balancing ischemic and bleeding risk—remains the real challenge.
Which of these studies do you think will most change practice in the next year?”
More posts featuring Bartosz Hudzik.
-
Sep 30, 2026, 13:29Abdus Salam: What Can CT Venography Reveal About the Veins?
-
Sep 30, 2026, 13:03Amira Mohy: Diagnostic Flow Cytometry Panels for Hematological Malignancies
-
Sep 30, 2026, 12:52Paul Watton: Could Repetitive Head Impacts Leave a Molecular Memory?
-
Sep 30, 2026, 12:41The Journey to ISTH 2027 Starts in Vancouver
-
Sep 30, 2026, 11:36Basit Ali: A Closer Look at CT Venography
-
Sep 30, 2026, 11:16Christina Pohlman: Could aPL Levels Help Predict Stroke Recurrence?
-
Sep 30, 2026, 10:55Rana Al Hrout: Diagnostic Approach to Hypochromic Microcytic Anemia
-
Sep 30, 2026, 01:52Javed Anees: DADA2 – When a Young Stroke Is More Than a Stroke
-
Sep 30, 2026, 01:51How a Venous Thrombus Becomes Revascularized – ISTH